Browsing: 190M

South Korea’s Hanmi Pharmaceutical signed an exclusive global licensing agreement Monday with Genentech, a Roche subsidiary, for HM17321 — an experimental obesity drug designed to selectively burn fat while simultaneously building muscle, attacking the single biggest clinical complaint about the blockbuster GLP-1 drug class: the lean mass patients lose alongside the weight. The deal is…